- Home
- THCH vs INAB Comparison
THCH vs INAB Comparison
Compare THCH & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THCH
- INAB
- Stock Information
- Founded
- THCH 2018
- INAB 2016
- Country
- THCH China
- INAB United States
- Employees
- THCH N/A
- INAB N/A
- Industry
- THCH Blank Checks
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- THCH Finance
- INAB Health Care
- Exchange
- THCH Nasdaq
- INAB Nasdaq
- Market Cap
- THCH 84.8M
- INAB 14.5M
- IPO Year
- THCH N/A
- INAB 2021
- Fundamental
- Price
- THCH $2.99
- INAB $2.30
- Analyst Decision
- THCH
- INAB Strong Buy
- Analyst Count
- THCH 0
- INAB 2
- Target Price
- THCH N/A
- INAB $108.00
- AVG Volume (30 Days)
- THCH 17.2K
- INAB 170.0K
- Earning Date
- THCH 08-28-2025
- INAB 08-07-2025
- Dividend Yield
- THCH N/A
- INAB N/A
- EPS Growth
- THCH N/A
- INAB N/A
- EPS
- THCH N/A
- INAB N/A
- Revenue
- THCH $187,384,526.00
- INAB N/A
- Revenue This Year
- THCH N/A
- INAB N/A
- Revenue Next Year
- THCH N/A
- INAB N/A
- P/E Ratio
- THCH N/A
- INAB N/A
- Revenue Growth
- THCH N/A
- INAB N/A
- 52 Week Low
- THCH $2.15
- INAB $2.05
- 52 Week High
- THCH $5.15
- INAB $27.30
- Technical
- Relative Strength Index (RSI)
- THCH 60.05
- INAB 39.46
- Support Level
- THCH $2.86
- INAB $2.10
- Resistance Level
- THCH $2.99
- INAB $2.30
- Average True Range (ATR)
- THCH 0.12
- INAB 0.14
- MACD
- THCH 0.01
- INAB 0.11
- Stochastic Oscillator
- THCH 100.00
- INAB 49.56
About THCH TH International Limited Ordinary shares
TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under single reportable segment, Tim Hortons. The company's revenue is derived from its operations in the PRC.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.